SLC5A2 and congestive heart failure: This subgroup of patients should be followed up in specialised centres for chronic heart failure patients and, in accordance with current guidelines, re-examinations, and possibly intensification of pharmacological treatments (increasing the dose of diuretics/ACE inhibitors/sartans/beta-blockers; replacing ACE inhibitors/sartans with sacubitril/valsartan; adding spironolactone/eplerenone, ivabradine, SGLT2 inhibitors or digoxin) and/or non-pharmacological treatments (revascularisation, ICD/CRT implantation, valvular heart disease surgery), might be considered.